TTOO
Income statement / Annual
Last year (2023), T2 Biosystems, Inc.'s total revenue was $7.19 M,
a decrease of 67.75% from the previous year.
In 2023, T2 Biosystems, Inc.'s net income was -$50.08 M.
See T2 Biosystems, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$7.19 M
|
$22.31 M
|
$28.06 M
|
$18.13 M
|
$8.34 M
|
$10.50 M
|
$4.67 M
|
$4.08 M
|
$2.81 M
|
$119,000.00
|
| Cost of Revenue |
$15.36 M |
$21.14 M |
$20.70 M |
$21.28 M |
$16.76 M |
$15.40 M |
$12.03 M |
$6.87 M |
$1.74 M |
$19.78 M |
| Gross Profit |
-$8.17 M |
$1.17 M |
$7.36 M |
-$3.15 M |
-$8.43 M |
-$4.90 M |
-$7.36 M |
-$2.79 M |
$1.07 M |
-$19.66 M |
| Gross Profit Ratio |
-1.14 |
0.05 |
0.26 |
-0.17 |
-1.01 |
-0.47 |
-1.58 |
-0.68 |
0.38 |
-165.24 |
| Research and Development
Expenses |
$14.15 M
|
$25.93 M
|
$21.80 M
|
$16.92 M
|
$16.33 M
|
$14.49 M
|
$23.73 M
|
$24.01 M
|
$25.36 M
|
$19.78 M
|
| General & Administrative
Expenses |
$0.00
|
$30.64 M
|
$0.00
|
$0.00
|
$0.00
|
$25.70 M
|
$22.76 M
|
$24.08 M
|
$19.09 M
|
$11.02 M
|
| Selling & Marketing
Expenses |
$0.00
|
$100,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$24.83 M
|
$30.74 M
|
$28.53 M
|
$21.29 M
|
$27.30 M
|
$25.70 M
|
$22.76 M
|
$24.08 M
|
$19.09 M
|
$11.02 M
|
| Other Expenses |
$2.51 M |
$31,000.00 |
$206,000.00 |
$62,000.00 |
$400,000.00 |
$619,000.00 |
$331,000.00 |
$172,000.00 |
$60,000.00 |
$12,000.00 |
| Operating Expenses |
$41.49 M |
$56.68 M |
$50.33 M |
$38.21 M |
$43.63 M |
$40.19 M |
$46.49 M |
$48.09 M |
$44.46 M |
$30.80 M |
| Cost And Expenses |
$56.86 M |
$77.82 M |
$71.03 M |
$59.49 M |
$60.39 M |
$55.59 M |
$58.52 M |
$54.96 M |
$46.20 M |
$30.80 M |
| Interest Income |
$0.00 |
$8,000.00 |
$112,000.00 |
$14,000.00 |
$1,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$5.34 M |
$6.08 M |
$6.59 M |
$5.50 M |
$7.35 M |
$6.68 M |
$8.91 M |
$4.10 M |
$1.97 M |
$721,000.00 |
| Depreciation &
Amortization |
$859,000.00
|
$2.27 M
|
$2.54 M
|
$3.16 M
|
$3.64 M
|
$2.45 M
|
$2.94 M
|
$2.28 M
|
$1.47 M
|
$691,000.00
|
| EBITDA |
-$43.88 M
|
-$55.20 M
|
-$41.13 M
|
-$38.49 M
|
-$48.30 M
|
-$41.96 M
|
-$50.58 M
|
-$48.43 M
|
-$41.86 M
|
-$29.98 M
|
| EBITDA Ratio |
-6.1 |
-2.49 |
-1.52 |
-2.28 |
-6.2 |
-4.24 |
-10.84 |
-12.43 |
-15.4 |
-257.72 |
| Operating Income Ratio
|
-6.9
|
-2.49
|
-1.53
|
-2.28
|
-6.25
|
-4.29
|
-11.54
|
-12.47
|
-15.42
|
-257.82
|
| Total Other
Income/Expenses Net |
-$413,000.00
|
-$6.81 M
|
-$6.27 M
|
-$5.44 M
|
-$6.95 M
|
-$6.06 M
|
-$8.58 M
|
-$3.93 M
|
-$1.91 M
|
-$709,000.00
|
| Income Before Tax |
-$50.08 M |
-$62.32 M |
-$49.24 M |
-$46.80 M |
-$59.01 M |
-$51.15 M |
-$62.43 M |
-$54.80 M |
-$45.29 M |
-$31.39 M |
| Income Before Tax Ratio
|
-6.96
|
-2.79
|
-1.75
|
-2.58
|
-7.08
|
-4.87
|
-13.38
|
-13.43
|
-16.1
|
-263.78
|
| Income Tax Expense |
$0.00 |
$1.05 M |
$4.25 M |
$2.41 M |
$4.11 M |
$619,000.00 |
$9.24 M |
$1.99 M |
$562,000.00 |
$42,000.00 |
| Net Income |
-$50.08 M |
-$63.37 M |
-$53.50 M |
-$49.21 M |
-$63.11 M |
-$51.15 M |
-$62.43 M |
-$54.80 M |
-$45.29 M |
-$31.39 M |
| Net Income Ratio |
-6.96 |
-2.84 |
-1.91 |
-2.71 |
-7.57 |
-4.87 |
-13.38 |
-13.43 |
-16.1 |
-263.78 |
| EPS |
-19.19 |
-1242.48 |
-1683.72 |
-2027.86 |
-6934.2 |
-126.12 |
-194.29 |
-210.66 |
-220.91 |
-361.85 |
| EPS Diluted |
-19.19 |
-1242.48 |
-1683.72 |
-2027.86 |
-6934.2 |
-126.12 |
-194.29 |
-210.66 |
-220.91 |
-361.85 |
| Weighted Average Shares
Out |
$2.61 M
|
$51,003.00
|
$31,772.00
|
$24,266.00
|
$9,101.55
|
$405,588.00
|
$321,315.00
|
$260,157.00
|
$205,017.00
|
$86,749.00
|
| Weighted Average Shares
Out Diluted |
$2.61 M
|
$51,003.00
|
$31,772.00
|
$24,266.00
|
$9,101.55
|
$405,588.00
|
$321,315.00
|
$260,157.00
|
$205,017.00
|
$86,749.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
